Track Solventum Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Solventum Corporation SOLV · Stock Open Solventum Corporation in new tab

89.08 USD
P/E
100.09
EPS
0.89
P/B
3.15
ROE
3.19
Beta
0.75
Target Price
98.38 USD
Solventum Corporation logo

Solventum Corporation

🧾 Earnings Recap – Q3 2026

Solventum rose 3.7% after earnings, as management reported Q3 organic growth and EPS above its plan despite the ERP cutover. The reaction appears to reflect confidence in execution and the separation milestone, though the call did not provide specific growth or EPS figures.

  • Management said all key financial metrics were in line with or ahead of expectations, with organic growth and EPS above plan; results included the reversal of advanced orders from the prior quarter.
  • The Americas ERP cutover is complete, and separation is now more than 90% complete. Management said separation costs rolling off should strengthen Q4 free cash flow.
  • A renegotiated long-term raw-material supply agreement with 3M supports supply continuity and is cited as a factor in improving year-over-year margins in 2027; management also noted the comparison will include a 2026 one-time tariff refund.
  • Solventum is evaluating both sale and spin options for Health Information Systems. Proceeds would primarily go toward paying down debt and returning capital to shareholders.
  • Management highlighted a large wound-care opportunity: V.A.C. therapy is used about 10% of the time, and studies cited on the call show wounds are ready for closure almost twice as fast and amputations are reduced 60% versus non-V.A.C. treatments.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E100.09
EPS0.89
Book Value28.27
Price to Book3.15
Debt/Equity110.18
% Insiders15.634%
Growth
Revenue Growth-0.07%
Earnings Growth0.04%
Estimates
Forward P/E11.81
Forward EPS7.54
Target Mean Price98.38

DCF valuation

Model fair value for Solventum Corporation (SOLV)
Result
Sign in to run the valuation for SOLV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Buy · mean target 98.38 USD (low 75.00, high 115.00) · as of 14 Nov 2026
Low 75.00
Mean 98.38
High 115.00
Price 89.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Solventum Corporation Logo Solventum Corporation Analysis (SOLV)

United States Healthcare Official Website Stock

Is Solventum Corporation a good investment? Solventum Corporation (SOLV) is currently trading at 89.08 USD. Market analysts have a consensus price target of 98.38 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 100.09. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Solventum Corporation is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 7.54.

Investor FAQ

Does Solventum Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Solventum Corporation?

Solventum Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 0.89.

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

Exchange Ticker
US83444M1018
SOLV
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion